Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas

NCT00004261 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00004261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 1999
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, head and neck cancer, prostate cancer, sarcoma